A detailed history of Vanguard Group Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,133,625 shares of NUVL stock, worth $347 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,133,625
Previous 3,776,016 9.47%
Holding current value
$347 Million
Previous $286 Million 47.63%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$67.44 - $112.17 $24.1 Million - $40.1 Million
357,609 Added 9.47%
4,133,625 $423 Million
Q2 2024

Aug 13, 2024

BUY
$62.76 - $81.61 $22.8 Million - $29.7 Million
363,944 Added 10.67%
3,776,016 $286 Million
Q1 2024

May 10, 2024

BUY
$72.35 - $88.99 $5.23 Million - $6.43 Million
72,222 Added 2.16%
3,412,072 $256 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $51.1 Million - $96.8 Million
1,205,668 Added 56.49%
3,339,850 $246 Million
Q3 2023

Nov 14, 2023

BUY
$39.12 - $49.85 $615,044 - $783,741
15,722 Added 0.74%
2,134,182 $98.1 Million
Q2 2023

Aug 14, 2023

BUY
$23.58 - $44.68 $1.14 Million - $2.15 Million
48,214 Added 2.33%
2,118,460 $89.3 Million
Q1 2023

May 15, 2023

BUY
$25.42 - $33.52 $1.47 Million - $1.94 Million
57,938 Added 2.88%
2,070,246 $54 Million
Q4 2022

Feb 10, 2023

BUY
$18.46 - $36.37 $10.6 Million - $20.8 Million
571,615 Added 39.68%
2,012,308 $59.9 Million
Q3 2022

Nov 14, 2022

BUY
$13.55 - $19.92 $2.45 Million - $3.6 Million
180,528 Added 14.33%
1,440,693 $28 Million
Q2 2022

Aug 12, 2022

SELL
$7.4 - $15.07 $2.79 Million - $5.69 Million
-377,342 Reduced 23.04%
1,260,165 $17.1 Million
Q1 2022

May 13, 2022

BUY
$11.65 - $19.57 $10.2 Million - $17.2 Million
877,835 Added 115.55%
1,637,507 $22.7 Million
Q4 2021

Feb 14, 2022

BUY
$18.01 - $30.1 $192,562 - $321,829
10,692 Added 1.43%
759,672 $14.5 Million
Q3 2021

Nov 12, 2021

BUY
$18.25 - $38.35 $13.7 Million - $28.7 Million
748,980 New
748,980 $16.9 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.6B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.